Encapsulation for improved manufacturing and controlled-delivery of therapeutic compounds

在开发有效的治疗产品时，药物的合成和提纯只是过程的一部分。同样重要的是要考虑药物将如何输送。脂质体或脂泡是一种有吸引力的给药功能化合物的传递系统。众所周知，脂质体系统可以延长药物保留时间，减少给药后的毒副作用。人们非常感兴趣的一个领域是，在吸入给药系统中使用脂质体，作为一种靶向、持续和非侵入性的方式将药物输送到肺部。脂质体包埋在生物可降解胶囊中的化合物微胶囊提供了一种可能的肺部给药途径，具有更高的稳定性和药物滞留率。这项研究有可能更有效地治疗结核病和糖尿病等疾病，而不需要痛苦的注射。这些好处无疑将改善许多患有此类疾病的加拿大人的健康和生活质量。

In the development of an effective therapeutic product, the synthesis and purification of the drug are only part of the process. It is also important to consider how the drug will be delivered. Liposomes or lipid vesicles are an attractive delivery system for administering functional compounds. Liposomal systems are known to increase drug retention time and to reduce toxic side effects after administration. One area of great interest is the use of liposomes in drug delivery systems administered by inhalation for a targeted, sustained and non-invasive means of delivering drugs to the lungs. The microencapsulation of liposome-entrapped compounds in biodegradable capsules offers a possible means of drug delivery to the lungs with increased stability and drug retention. This research has the potential for treating diseases such as tuberculosis and diabetes more effectively and without painful injections. Such benefits will undoubtedly improve the health and quality of life of the many Canadians who suffer from such diseases.